Caribou Biosciences, Inc.CRBUEarnings & Financial Report
Nasdaq
NextMar 30, 2026
CRBU Q3 2025 Key Financial Metrics
Revenue
$2.2M
Gross Profit
N/A
Operating Profit
$-29.4M
Net Profit
$-27.5M
Gross Margin
N/A
Operating Margin
-1337.6%
Net Margin
-1253.3%
YoY Growth
8.6%
EPS
$-0.30
Financial Flow
Caribou Biosciences, Inc. Q3 2025 Financial Summary
Caribou Biosciences, Inc. reported revenue of $2.2M for Q3 2025, with a net profit of $-27.5M (-1253.3% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $2.2M |
|---|---|
| Net Profit | $-27.5M |
| Gross Margin | N/A |
| Operating Margin | -1337.6% |
| Report Period | Q3 2025 |
Caribou Biosciences, Inc. Annual Revenue by Year
Caribou Biosciences, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $10.0M).
| Year | Annual Revenue |
|---|---|
| 2024 | $10.0M |
| 2023 | $34.5M |
| 2022 | $13.9M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.6M | $2.4M | $3.5M | $2.0M | $2.1M | $2.4M | $2.7M | $2.2M |
| YoY Growth | -3.6% | -30.6% | -7.7% | -91.4% | -41.6% | -3.1% | -23.0% | 8.6% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $432.2M | $406.8M | $372.9M | $344.3M | $313.3M | $273.7M | $220.9M | $195.0M |
| Liabilities | $63.8M | $63.5M | $62.5M | $63.1M | $60.4M | $56.4M | $54.8M | $53.1M |
| Equity | $368.4M | $343.3M | $310.5M | $281.2M | $253.0M | $217.2M | $166.1M | $141.8M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-21.4M | $-37.2M | $-32.9M | $-32.7M | $-35.5M | $-36.7M | $-28.3M | $-25.2M |